Drug Profile


Alternative Names: ATI-5000; ATI-5923

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator ARYx Therapeutics
  • Developer Armetheon
  • Class Anticoagulants; Small molecules
  • Mechanism of Action Vitamin K epoxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Thromboembolism; Thrombosis

Most Recent Events

  • 14 Feb 2017 Phase-III clinical trials in Thrombosis (Prevention) in USA (PO) before February 2017 (Armetheon Pipeline, February 2017)
  • 14 Feb 2017 The European Medicines Agency Scientific Advice Working Group advises that Armetheon conduct a pivotal phase III trial for Thromboembolism and Thrombosis (Prevention)
  • 09 Feb 2017 Pharmacokinetics, pharmacodynamics and adverse events data from three clinical trials in Healthy volunteers released by Armetheon (9211514; 3226868)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top